AstraZeneca is trading 3.02% up at $164.93 after positive Phase III results for Tagrisso plus savolitinib and Enhertu in non-small-cell lung cancer.
- Encouraging oncology updates appear to outweigh the simultaneous discontinuation of the unsuccessful volrustomig trial.
- Healthcare-sector strength is adding support, with the sector rallying alongside positive Moderna trial news and easing bond yields.